Longevity Health Holdings Announces Merger with THPlasma and Termination of 20/20 BioLabs Transaction

Company Overview - Longevity Health Holdings, Inc. focuses on human longevity and healthy aging, recently announcing a merger with True Health Inc., a key player in the plasma collection industry [1][2] - True Health operates under the THPlasma brand and has established a growing network of plasma collection centers in the Northeast United States [7] Merger Details - The merger is an all-stock transaction, with the combined company expected to continue trading on Nasdaq under the symbol "XAGE" [1] - The merger follows Longevity's previous acquisitions of Carmell Therapeutics and Elevai Skincare, enhancing its capabilities in plasma-derived growth factors and exosomes [2] Industry Context - The United States supplies over 60% of the world's plasma but faces a shortfall in plasma and plasma-derived therapeutics, creating a significant market opportunity for THPlasma [3] - THPlasma is addressing this shortfall with a rapidly expanding footprint of plasma collection centers [3] Financial Highlights - THPlasma has guaranteed sales offtake agreements for up to $100 million annually and achieved cash profitability in FY2024 [8] - Projected FY2025 revenue for THPlasma is estimated at $10 million, with EBITDA of $2 million and net income of $1 million, while FY2026 estimates show revenue growth to $32 million, EBITDA of $7 million, and net income of $4 million [8] Strategic Vision - The merger is expected to unlock access to public markets and future M&A opportunities, with both companies' leadership expressing optimism about growth and value creation [6][8] - Longevity aims to drive further growth in THPlasma through both acquisitions and organic growth strategies [6]